blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3411058

EP3411058 - COMBINATION THERAPY WITH A6 AND PACLITAXEL FOR THE TREATMENT OF OVARIAN CANCER [Right-click to bookmark this link]
Former [2018/50]COMBINATION THERAPY WITH A6, CHEMOTHERAPEUTIC AGENTS, RADIATION THERAPY, OR A COMBINATION THEREOF FOR THE TREATMENT OF CANCER
[2022/22]
StatusNo opposition filed within time limit
Status updated on  12.01.2024
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  03.02.2023
FormerGrant of patent is intended
Status updated on  26.07.2022
FormerExamination is in progress
Status updated on  19.02.2021
FormerRequest for examination was made
Status updated on  09.11.2018
FormerThe international publication has been made
Status updated on  11.08.2017
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Splash Pharmaceuticals, Inc.
4365 Executive Drive
Suite 1500
San Diego, CA 92121 / US
[2023/10]
Former [2018/50]For all designated states
Splash Pharmaceuticals, Inc.
4365 Executive Drive
Suite 1500
San Diego, CA 92121 / US
Inventor(s)01 / FINLAYSON, Malcolm
c/o Splash Pharmaceuticals
4365 Executive Drive
Suite 1500
San Diego, CA 92121 / US
02 / NELSON, David
c/o Splash Pharmaceuticals
4365 Executive Drive
Suite 1500
San Diego, CA 92121 / US
 [2018/50]
Representative(s)Meissner Bolte Partnerschaft mbB
Patentanwälte Rechtsanwälte
Postfach 86 06 24
81633 München / DE
[N/P]
Former [2023/10]Held, Stephan, et al
Meissner Bolte Patentanwälte
Rechtsanwälte Partnerschaft mbB
Widenmayerstraße 47
80538 München / DE
Former [2018/50]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
Application number, filing date17747995.331.01.2017
[2018/50]
WO2017US15754
Priority number, dateUS201662290306P02.02.2016         Original published format: US 201662290306 P
US201662314867P29.03.2016         Original published format: US 201662314867 P
US201662368964P29.07.2016         Original published format: US 201662368964 P
[2018/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017136312
Date:10.08.2017
Language:EN
[2017/32]
Type: A1 Application with search report 
No.:EP3411058
Date:12.12.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 10.08.2017 takes the place of the publication of the European patent application.
[2018/50]
Type: B1 Patent specification 
No.:EP3411058
Date:08.03.2023
Language:EN
[2023/10]
Search report(s)International search report - published on:US10.08.2017
(Supplementary) European search report - dispatched on:EP02.08.2019
ClassificationIPC:A61K45/06, A61K31/337, A61K33/243, A61K38/08, C07K7/06, A61P35/00, A61P35/04
[2022/22]
CPC:
C07K7/06 (EP); A61K45/06 (EP,US); A61K31/337 (EP,US);
A61K33/243 (EP,US); A61K38/08 (EP,US); A61P35/00 (EP);
A61P35/04 (EP); A61K31/351 (US); A61K31/555 (US) (-)
C-Set:
A61K31/337, A61K2300/00 (EP);
A61K33/243, A61K2300/00 (EP);
A61K38/08, A61K2300/00 (EP)
Former IPC [2018/50]A61K38/04, A61K38/08, C07K7/06, A61P35/00, A61P35/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/50]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:KOMBINATIONSTHERAPIE MIT A6 UND PACLITAXEL ZUR BEHANDLUNG DES OVARIALKARZINOMS[2022/22]
English:COMBINATION THERAPY WITH A6 AND PACLITAXEL FOR THE TREATMENT OF OVARIAN CANCER[2022/22]
French:POLYTHÉRAPIE AVEC A6 ET PACLITAXEL POUR LE TRAITEMENT DU CANCER DES OVAIRES[2022/22]
Former [2018/50]KOMBINATIONSTHERAPIE MIT A6, CHEMOTHERAPEUTIKA, STRAHLENTHERAPIE ODER KOMBINATION DAVON ZUR BEHANDLUNG VON KREBS
Former [2018/50]COMBINATION THERAPY WITH A6, CHEMOTHERAPEUTIC AGENTS, RADIATION THERAPY, OR A COMBINATION THEREOF FOR THE TREATMENT OF CANCER
Former [2018/50]POLYTHÉRAPIE AVEC A6, AGENTS DE CHIMIOTHÉRAPIE, RADIOTHÉRAPIE OU UNE COMBINAISON DE CES DENIERS POUR LE TRAITEMENT DU CANCER
Entry into regional phase27.07.2018National basic fee paid 
27.07.2018Search fee paid 
27.07.2018Designation fee(s) paid 
27.07.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
27.07.2018Examination requested  [2018/50]
02.03.2020Amendment by applicant (claims and/or description)
18.02.2021Despatch of a communication from the examining division (Time limit: M06)
30.08.2021Reply to a communication from the examining division
27.07.2022Communication of intention to grant the patent
03.01.2023Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
16.01.2023Fee for grant paid
16.01.2023Fee for publishing/printing paid
16.01.2023Receipt of the translation of the claim(s)
Opposition(s)11.12.2023No opposition filed within time limit [2024/07]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
16.01.2023Request for further processing filed
16.01.2023Full payment received (date of receipt of payment)
Request granted
24.01.2023Decision despatched
Fees paidRenewal fee
15.01.2019Renewal fee patent year 03
30.01.2020Renewal fee patent year 04
27.01.2021Renewal fee patent year 05
27.01.2022Renewal fee patent year 06
27.01.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
IT08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
[2024/26]
Former [2024/10]AT08.03.2023
CZ08.03.2023
DK08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SI08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/50]AT08.03.2023
CZ08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
PL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SK08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
IS08.07.2023
PT10.07.2023
Former [2023/49]AT08.03.2023
CZ08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RO08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/48]AT08.03.2023
EE08.03.2023
ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/46]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
SM08.03.2023
NO08.06.2023
GR09.06.2023
PT10.07.2023
Former [2023/38]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
NL08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
GR09.06.2023
Former [2023/37]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
GR09.06.2023
Former [2023/36]ES08.03.2023
FI08.03.2023
HR08.03.2023
LT08.03.2023
LV08.03.2023
RS08.03.2023
SE08.03.2023
NO08.06.2023
Former [2023/35]ES08.03.2023
HR08.03.2023
LT08.03.2023
RS08.03.2023
NO08.06.2023
Former [2023/34]ES08.03.2023
LT08.03.2023
RS08.03.2023
Former [2023/33]ES08.03.2023
LT08.03.2023
Documents cited:Search[XY]WO2010102253  (ANGSTROM PHARMACEUTICALS INC [US], et al) [X] 1,4,6,7,9-11 * whole ddocument esp. pages 1-2,4,7,12,21,25;claims 46,57-61 * [Y] 1-15;
 [Y]WO2011022335  (SINAI SCHOOL MEDICINE [US], et al) [Y] 1-15* whole document esp.paragraphs [16,92,94,95,97,98,127,129,252-253,260] *;
 [XY]WO2011109678  (ANGSTROM PHARMACEUTICALS INC [US], et al) [X] 1,4,6,7,9-11 * whole document esp. paragraphs [2,30,35,38,41,43,44,54,59,90,105,197,207,266]; claim 1 * [Y] 1-15
International search[Y]US2006088511  (TAI ISABELLA T [CA], et al) [Y] 27, 30* para [0211], [0214] *;
 [XY]US2011053864  (FINLAYSON MALCOLM [US], et al) [X] 1-6, 24-26, 28, 29, 33-38, 55-58 * para [0035], [0043], [0052], [0056], [0104], [0107], [0109], [0142], [0189] SEQ ID NO: 1 * [Y] 27, 30
by applicantUS5994309
 US6696416
 US6963587
 US2009192085
    - "Peptidomimetics for Drug Design", GOODMANRO, Burger's Medicinal Chemistry and Drug Discovery, John Wiley & Sons, (19950000), vol. 1, pages 803 - 861
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.